- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00043355
Safety and Efficacy of Inhaled Interferon Gamma-1b in Pulmonary MAC Infection
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Safety and Efficacy of Inhaled Interferon Gamma-1b With Antimycobacterials in Previously Treated or Mod-to-Sev Pulmonary Mycobacterium Avium Complex Infection
The purpose of this research study is to test the safety and effectiveness of inhaled Interferon gamma-1b (IFN-g 1b), when administered for 48 weeks and in combination with oral antibiotics which may be administered for up to 72 weeks for the treatment of a lung infection caused by a bacterium called Mycobacterium avium complex .
FDA has not approved Interferon gamma-1b for use in patients with MAC infection of the lungs, which is the purpose of this study.Interferon gamma-1b and similar proteins play important roles in establishing and maintaining protective immune responses against a variety of microorganisms.
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Male and female patients, 18 years of age or older, with bacteriologically and radiographically confirmed pulmonary MAC infection who have been treated for their infection for at least 6 months within the previous 2 years, as well as patients with moderate or severe pulmonary disease due to MAC, not previously treated for this infection. Patients with recurrent pulmonary MAC infection after previous successful treatment for pulmonary MAC disease are also eligible.
In addition, various laboratory testing must confirm conditions. Patients cannot be positive for HIV or have an extra-pulmonary (in general, outside of the lungs) infection of MAC. Other preconditions related to health or other conditions exist as factors for inclusion or exclusion from this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
sustained culture conversion
Time Frame: 52 weeks
|
52 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GIMAC-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Infection
-
University Hospital, GrenobleTerminatedLung InfectionFrance
-
Capital Medical UniversityCancer Institute and Hospital, Chinese Academy of Medical Sciences; China-Japan...UnknownLung Transplant Rejection | Lung Transplant InfectionChina
-
Washington University School of MedicineCompletedLung Transplant InfectionUnited States
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingColorectal Cancer | Lung Cancer | Bevacizumab | Operation Wound; InfectionChina
-
Adams Respiratory TherapeuticsCompletedBronchitis | Acute Respiratory Infection | RhinosinusitisUnited States
-
Insmed IncorporatedCompletedNTM Lung Infection Due to MAC
-
Xlear, IncMetanoic Health Ltd.Not yet recruitingRespiratory Viral Infection
-
Hanmi Pharmaceutical Company LimitedUnknownAcute Upper Respiratory Infection | Acute BronchitisKorea, Republic of
-
The AlfredThe Alfred Research Trusts Small Project Grant.; Dr Carey Denholm and Laura...CompletedLower Respiratory Tract Infection | Lung Transplant InfectionAustralia
-
Centro Universitário Augusto MottaCompleted
Clinical Trials on interferon gamma-1b
-
Nantes University HospitalActive, not recruiting
-
National Cancer Institute (NCI)CompletedRecurrent Mycosis Fungoides and Sezary Syndrome | Refractory Mycosis Fungoides and Sezary Syndrome | Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7 | Stage IIIA Mycosis... and other conditionsUnited States
-
Children's Hospital of PhiladelphiaFriedreich's Ataxia Research Alliance; Vidara Therapeutics Research LtdCompleted
-
InterMuneTerminatedPeritoneal Carcinoma | Ovarian CarcinomaUnited States
-
InterMuneCompletedPulmonary Fibrosis | Lung DiseaseUnited States
-
InterMuneCompletedCystic FibrosisUnited States
-
InterMuneCompleted
-
AmgenCompleted
-
InterMuneTerminatedIdiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Lung DiseaseUnited States
-
InterMuneTerminatedIdiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Lung DiseaseUnited States